Bavisant has been in phase II clinical trials by Johnson & Johnson for the treatment of attention deficit hyperactivity disorder (ADHD). However, no recent development has been reported.
|CAS No.||929622-08-2 (Bavisant);|
|Chemical Name||Methanone, (4-cyclopropyl-1-piperazinyl)[4-(4-morpholinylmethyl)phenyl]-|
|Bavisant （Free Acid/Base）Parameters：|
|*：Calculated by ACD/Labs software V11.02.|